Glucagon-like peptide-1 receptor PET/CT with 68Ga-NOTA-Exendin-4 for detecting localized insulinoma: A prospective cohort study

Journal of Nuclear Medicine

Volumn 57, Issue 5, 2016, Pages 715-720

  Luo, Yaping ^a   Pan, Qingqing ^a   Yao, Shaobo ^a   Yu, Miao ^a   Wu, Wenming ^a   Xue, Huadan ^a   Kiesewetter, Dale O ^b   Zhu, Zhaohui ^a   Li, Fang ^a   Zhao, Yupei ^a   Chen, Xiaoyuan ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Exendin 4; Glucagon like peptide 1 receptor (GLP 1R); Insulinoma; PET CT

Indexed keywords

99MTC HYDRAZINONICOTINAMIDE TOC; GALLIUM 68 NOTA EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; TRACER; UNCLASSIFIED DRUG; 1,4,7-TRIAZACYCLONONANE-N,N',N''-TRIACETIC ACID; EXENDIN 4; GALLIUM; HETEROCYCLIC COMPOUND; PEPTIDE; VENOM;

ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENDOGENOUS HYPERINSULINEMIC HYPOGLYCEMIA; ENDOSCOPIC ULTRASONOGRAPHY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOGLYCEMIA; INSULINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ADOLESCENT; CHEMISTRY; CLINICAL TRIAL; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; COHORT STUDIES; FEMALE; GALLIUM RADIOISOTOPES; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HETEROCYCLIC COMPOUNDS; HUMANS; INSULINOMA; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PEPTIDES; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; VENOMS; YOUNG ADULT;

EID: 84966784621     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.167445     Document Type: Article

References (32)

1. Fidler JL, Fletcher JG, Reading CC, et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. AJR. 2003;181:775-780.
2. McAuley G, Delaney H, Colville J, et al. Multimodality preoperative imaging of pancreatic insulinomas. Clin Radiol. 2005;60:1039-1050.
3. Sotoudehmanesh R, Hedayat A, Shirazian N, et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine. 2007;31:238-241.
4. Rostambeigi N, Thompson GB. What should be done in an operating room when an insulinoma cannot be found? Clin Endocrinol (Oxf). 2009;70:512-515.
5. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19:783-798.
6. Krenning EP, Kwekkeboom DJ, Reubi JC, et al. 111In-octreotide scintigraphy in oncology. Metabolism. 1992;41:83-86.
7. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
8. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-793.
9. Körner M, Christ E, Wild D, Reubi JC. Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. Front Endocrinol (Lausanne). 2012;3:158.
10. Wild D, Macke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med. 2008;359:766-768.
11. Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94:4398-4405.
12. Sowa-Staszczak A, Pach D, Mikolajczak R, et al. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging. 2013;40:524-531.
13. Christ E, Wild D, Ederer S, et al. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: A prospective multicentre imaging study. Lancet Diabetes Endocrinol. 2013;1:115-122.
14. Wild D, Wicki A, Mansi R, et al. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med. 2010;51:1059-1067.
15. Gao H, Niu G, Yang M, et al. PET of insulinoma using 18F-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm. 2011;8:1775-1782.
16. Wu Z, Todorov I, Li L, et al. In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-exendin-4 by targeting GLP-1 receptor. Bioconjug Chem. 2011; 22:1587-1594.
17. Connolly BM, Vanko A, McQuade P, et al. Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist. Mol Imaging Biol. 2012;14:79-87.
18. Kiesewetter DO, Gao H, Ma Y, et al. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging. 2012;39:463-473.
19. Kiesewetter DO, Guo N, Guo J, et al. Evaluation of an [18F]AlF-NOTA analog of exendin-4 for imaging of GLP-1 receptor in insulinoma. Theranostics. 2012;2:999-1009.
20. Wang Y, Lim K, Normandin M, Zhao X, Cline GW, Ding YS. Synthesis and evaluation of [18F]exendin-(9-39) as a potential biomarker to measure pancreatic beta-cell mass. Nucl Med Biol. 2012;39:167-176.
21. Selvaraju RK, Velikyan I, Johansson L, et al. In vivo imaging of the glucagon like peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4. J Nucl Med. 2013;54:1458-1463.
22. Wu Z, Liu S, Hassink M, et al. Development and evaluation of 18F-TTCO-Cys40-exendin-4: A PET probe for imaging transplanted islets. J Nucl Med. 2013;54:244-251.
23. Wu H, Liang S, Liu S, Pan Y, Cheng D, Zhang Y. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals. Nucl Med Commun. 2013;34:701-708.
24. Mikkola K, Yim CB, Fagerholm V, et al. 64Cu-and 68Ga-labelled [Nle14,Lys40(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats. Mol Imaging Biol. 2014;16:255-263.
25. Jodal A, Lankat-Buttgereit B, Brom M, Schibli R, Behe M. A comparison of three 67/68Ga-labelled exendin-4 derivatives for beta-cell imaging on the GLP-1 receptor: The influence of the conjugation site of NODAGA as chelator. EJNMMI Res. 2014;4:31.
26. Antwi K, Fani M, Nicolas G, et al. Localization of hidden insulinomas with 68Ga-DOTA-exendin-4 PET/CT: A pilot study. J Nucl Med. 2015;56:1075-1078.
27. Luo Y, Yu M, Pan Q, et al. 68Ga-NOTA-exendin-4 PET/CT in detection of occult insulinoma and evaluation of physiological uptake. Eur J Nucl Med Mol Imaging. 2015;42:531-532.
28. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009;94:709-728.
29. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007;113:546-593.
30. Wild D, Christ E, Caplin ME, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med. 2011;52:1073-1078.
31. Placzkowski KA, Vella A, Thompson GB, et al. Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab. 2009;94:1069-1073.
32. Christ E, Wild D, Antwi K, et al. Preoperative localization of adult nesidioblastosis using Ga-DOTA-exendin-4-PET/CT. Endocrine. 2015;50:821-823.